Riboflavin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Riboflavin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Riboflavin.
Dosing Protocols
Beginner — routine dietary adequacy. Most adults with regular consumption of dairy, eggs, meat, or fortified grains meet the RDA (1.3 mg/day men, 1.1 mg/day women) without supplementation. A basic multivitamin containing 1.5-10 mg riboflavin covers any gaps. Food sources: milk (1 cup ≈ 0.4 mg), yogurt, eggs, beef, pork, chicken liver, almonds, fortified breakfast cereals, spinach, mushrooms. Vegetarians and especially vegans should pay particular attention because plant sources are generally lower in bioavailable riboflavin than animal products; a multivitamin with B-complex is reasonable. Pregnancy (1.4 mg RDA) and lactation (1.6 mg RDA) are typically covered by a prenatal multivitamin. No pharmacologic dose at beginner tier for general wellness purposes.
Intermediate — migraine prophylaxis and MTHFR-targeted therapy. For episodic migraine prevention with ≥4 attack days per month or disabling migraine, riboflavin 400 mg/day for 3 months is evidence-based Level B preventive therapy (Schoenen 1998, PMID 9484373); typically taken as a single 400 mg dose with breakfast or split 200 mg twice daily. Expect 2-3 months to see benefit — do not discontinue prematurely. If effective, continue indefinitely with periodic trial of lower dose (200-300 mg/day) after 6-12 months. Often combined with magnesium 400-600 mg/day (see Magnesium) and CoQ10 100-300 mg/day (see CoQ10) for comprehensive mitochondrial/migraine support stack — each component has independent AHS Level B/C evidence. For MTHFR C677T homozygotes with elevated blood pressure, riboflavin 1.6 mg/day (contained in a standard B-complex or taken as standalone) for 4-6 months reduces SBP by 6-13 mmHg in 10-15% of European-ancestry individuals with this genotype (McNulty trials). Order MTHFR genotype testing first; if 677TT confirmed, add riboflavin to standard antihypertensive regimen rather than replacing evidence-based BP therapy. For hyperhomocysteinemia with MTHFR 677TT, riboflavin 5-10 mg/day + folate + B12 + B6 reduces homocysteine more effectively than folate + B12 + B6 alone. For glutaric aciduria I, MADD riboflavin-responsive, or Brown-Vialetto-Van Laere syndrome, pediatric metabolic specialist supervision; intermediate tier is not appropriate.
Advanced — high-dose metabolic and genetic disorder protocols. For Brown-Vialetto-Van Laere syndrome (SLC52A2/SLC52A3) and Fazio-Londe syndrome, aggressive high-dose oral riboflavin 10-80 mg/kg/day (often 1000-1500 mg/day in divided doses, up to 2000 mg/day in some pediatric protocols) can halt and partially reverse neurological deterioration — initiated immediately upon clinical suspicion and genetic confirmation, continued lifelong under pediatric neurology/metabolic specialist care. Delayed diagnosis worsens outcomes. For riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (RR-MADD/GA2), pharmacologic riboflavin 100-400 mg/day reverses characteristic acylcarnitine and organic acid abnormalities within weeks, often with dramatic clinical improvement in muscle weakness, lipid storage myopathy, and encephalopathy. For glutaric aciduria type I (GA1), combination therapy includes riboflavin 50-300 mg/day, L-carnitine, and protein restriction with lysine/tryptophan limitation. For refractory migraine prophylaxis where standard doses have failed, some centers use riboflavin up to 600 mg/day divided; evidence is extrapolated from lower-dose trials. For sickle cell disease antioxidant support, experimental protocols of riboflavin 50-100 mg/day have shown modest hematologic benefit in small trials. For corneal crosslinking in progressive keratoconus, topical riboflavin 0.1% plus UVA 370 nm at 3 mW/cm² for 30 minutes (Dresden protocol) or 10 mW/cm² for 9 minutes (accelerated protocol) under ophthalmologist administration; office-based procedure with typical 24-72 hour recovery. All high-dose and specialized protocols require physician supervision and specific clinical indication.
Commonly Stacked With
Riboflavin stacks with several other compounds in biologically meaningful ways. B-complex co-administration: riboflavin sits alongside B1 (thiamine), B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folate), and B12 (cobalamin) in overlapping metabolic pathways, and several of them have interdependent biochemistry. The folate-methylation cycle dependency: MTHFR is FAD-dependent (riboflavin-derived), 5-methylTHF generation requires FAD and NADPH and produces the methyl donor for homocysteine remethylation; MTHFR 677TT genotype responds to riboflavin via FAD cofactor stabilization. B6 activation dependency: PNPO (pyridoxine-5-phosphate oxidase) is FMN-dependent, so B6 functional status requires adequate B2; severe B2 deficiency impairs B6 utilization even with adequate B6 intake (see the Vitamin B6 entry). Niacin synthesis dependency: kynurenine monooxygenase (KMO) is FAD-dependent, so endogenous tryptophan-to-NAD+ conversion requires adequate B2 (see the Niacin entry). Mitochondrial stack for migraine: CoQ10 100-300 mg/day + riboflavin 400 mg/day + magnesium 400-600 mg/day is a widely-used non-prescription migraine prophylaxis stack supported by AHS Level B evidence for each component; combining all three addresses different aspects of mitochondrial dysfunction and neurovascular reactivity in migraine pathophysiology (see the CoQ10 and Magnesium entries). Glutathione support stack: riboflavin (for glutathione reductase regeneration of GSH), NAC (cysteine precursor), alpha-lipoic acid (thiol antioxidant), and selenium (glutathione peroxidase cofactor) support the glutathione redox system at multiple points. Corneal crosslinking with UVA: topical riboflavin 0.1% is the photosensitizer; UVA 370 nm is the activating wavelength; the combination is the core of the procedure and not interchangeable with other sensitizers. Riboflavin + L-carnitine + protein restriction: the standard GA1 and MADD triad. Riboflavin + folate + B12 + B6: homocysteine-lowering combination; riboflavin contribution is primarily via MTHFR stabilization in 677TT genotype. Riboflavin + magnesium + melatonin: migraine prophylaxis stacking with evidence for each component. MAO inhibitor antidepressants: MAO is FAD-dependent; patients on MAOIs do not have increased riboflavin requirement because the enzyme-drug interaction is at the active site level. Phenothiazine or TCA therapy: may increase riboflavin requirement through competitive transport inhibition; consider increased B2 intake in long-term therapy. The cleanest stacking summary: riboflavin pairs with the full B-complex in metabolic cycles (especially MTHFR/FAD-folate/B6-PNPO connections), with CoQ10 and magnesium in the evidence-based migraine prophylaxis trio, with glutathione system supports (NAC, ALA, selenium) for redox biology, and with specific partners for metabolic conditions (L-carnitine for GA1/MADD, topical UVA for keratoconus). See the Thiamine, Niacin, Vitamin B6, Folate, Vitamin B12, and Choline entries for the full B-complex network; CoQ10 and Magnesium for the migraine stack; Alpha-Lipoic Acid for the mitochondrial cofactor complement; Iron for the shared kynurenine/cytochrome contexts.
Side Effects & Safety
Contraindications
There are no absolute contraindications to oral riboflavin at RDA-range or pharmacologic doses; the vitamin has an exceptionally clean safety profile. Relative contraindications and cautions: **Known hypersensitivity** to riboflavin or to excipients in a particular formulation. **Pregnancy**: RDA-range riboflavin (1.4 mg/day) is safe and required; pharmacologic doses for migraine prophylaxis (400 mg/day) have not been systematically studied in large pregnancy cohorts but have an excellent general safety profile and are reasonable under obstetric/neurology supervision; lacking prospective RCT data, some clinicians prefer to use dietary and lower-dose options first in pregnancy. **Breastfeeding**: RDA to modest pharmacologic doses are safe; high-dose protocols for specific genetic disorders require specialist supervision. **Pediatric use**: RDA-range riboflavin is essential; pharmacologic doses for migraine prophylaxis (200-400 mg/day) have modest evidence and are widely used given safety; high-dose protocols for BVVL, MADD, and GA1 are pediatric metabolic specialist territory. **Phenothiazine, tricyclic antidepressant, or doxorubicin therapy**: increased riboflavin requirement possible; not a contraindication but may warrant monitoring. **Photodynamic therapy with other photosensitizers**: corneal crosslinking with riboflavin + UVA should not be combined with other photosensitizing agents. **Active herpes simplex keratitis** is a relative contraindication to corneal crosslinking (risk of reactivation). **Corneal thickness <400 microns** after epithelial removal is a contraindication to standard-intensity UVA crosslinking (risk of endothelial damage); hypotonic riboflavin swelling can compensate in borderline cases. **No clinically important absolute drug-drug contraindications** to oral riboflavin supplementation. **Renal failure**: riboflavin is renally cleared but has no reported accumulation toxicity; no dose adjustment generally needed for oral supplementation. **Hepatic failure**: riboflavin phosphorylation occurs predominantly in peripheral tissues rather than liver; no dose adjustment needed for mild-moderate hepatic impairment. The principal practical caution is to choose appropriate dose for indication: RDA range for general adequacy, 1.6 mg/day for MTHFR 677TT BP indication, 400 mg/day for migraine prophylaxis, and kg-weight-based high doses for specific genetic disorders under specialist care.
Additional Notes
The adult RDA for riboflavin is 1.3 mg/day for men, 1.1 mg/day for women, 1.4 mg/day in pregnancy, 1.6 mg/day in lactation. Pediatric RDAs scale from 0.3 mg/day in infants to 0.9-1.3 mg/day in adolescents. There is no formally established tolerable upper intake level because of absent toxicity signal across the studied dose range. Oral absorption is saturable via RFVT3 at approximately 20-27 mg per single oral dose; higher daily doses should be divided into multiple administrations for maximum delivery. Riboflavin 5-10 mg tablets, 25-100 mg tablets, 100-200 mg capsules, and topical 0.1% ophthalmic solutions are widely available. Riboflavin sodium phosphate (FMN) is the injectable and some pediatric oral forms. Pharmacologic doses for migraine: 400 mg/day as single morning dose or 200 mg BID; for MTHFR 677TT: 1.6 mg/day or 5-10 mg/day; for BVVL/MADD: 10-80 mg/kg/day under specialist care. Food sources: milk (0.4 mg per cup), yogurt, eggs (0.2 mg per large egg), beef liver (3 mg per 3 oz serving — extraordinarily rich), beef (0.3 mg per 3 oz), chicken breast (0.1 mg per 3 oz), almonds (0.3 mg per ounce), fortified breakfast cereals (often 1-2 mg per serving), spinach (0.2 mg per cup cooked), mushrooms (0.5 mg per cup portobello), asparagus, broccoli. Riboflavin is destroyed by UV light — the reason milk is sold in opaque containers or light-blocking plastic; clear glass milk bottles left in sunlight lose riboflavin within hours. Riboflavin is stable to heat in typical cooking; alkaline cooking conditions (baking soda added to vegetables) accelerate destruction. The bright yellow-orange fluorescent urine at pharmacologic doses is harmless and indicates the body is excreting unmetabolized riboflavin. Plasma riboflavin half-life is 66-84 minutes; tissue retention via FMN/FAD binding to apoenzymes is much longer. Functional assessment uses erythrocyte glutathione reductase activity coefficient (EGRAC): ratio >1.40 indicates deficiency, 1.20-1.40 marginal, <1.20 adequate. Whole-blood or erythrocyte FAD/FMN concentrations are less commonly measured. Routine lab monitoring for chronic pharmacologic riboflavin is unnecessary given the excellent safety profile.
Frequently Asked Questions
What is the recommended Riboflavin dosage?
Dosage for Riboflavin varies by protocol. Consult a qualified healthcare provider.
How often should I take Riboflavin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Riboflavin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Riboflavin side effects?
Riboflavin has an exceptionally clean safety profile — it is among the safest vitamins known, with no established tolerable upper intake level and no reported organ toxicity even at gram-per-day doses used for genetic transport disorders. The saturable intestinal absorption (~20-27 mg maximum per single oral dose) means that much of a high oral dose is not absorbed and passes into the colon or is excreted — excess is efficiently cleared via the kidneys as unmetabolized riboflavin, producing the characteristic **bright yellow-orange fluorescent urine** that users often notice within hours of taking a supplement. This urinary color is cosmetic only and carries no clinical significance. Similarly, perspiration and other body secretions can take on a faint yellow tint at high intakes. **Minor adverse effects at pharmacologic oral doses** include occasional nausea, mild diarrhea, and rarely itching at oral riboflavin 200-400 mg/day for migraine prophylaxis. These are uncommon and generally do not require discontinuation. Splitting the daily dose into 200 mg BID or 100 mg QID reduces GI upset in sensitive individuals. **Photosensitivity** has been reported rarely at pharmacologic doses — patients on migraine-dose riboflavin should use reasonable sun protection, though severe photosensitivity reactions are unusual. **Drug interactions**. Phenothiazines (chlorpromazine and related antipsychotics), tricyclic antidepressants (amitriptyline, imipramine, nortriptyline), and doxorubicin chemotherapy compete with riboflavin for intestinal transport and cellular phosphorylation; patients on long-term phenothiazine or TCA therapy may have increased riboflavin requirement. Probenecid reduces renal clearance of riboflavin. Oral contraceptives modestly reduce circulating riboflavin. Anticonvulsants (phenobarbital, phenytoin) increase riboflavin catabolism. Chronic alcohol impairs absorption, phosphorylation, and storage. Antibiotics (sulfonamides, tetracyclines) can interact through competing transport. **Drug-nutrient interaction of clinical interest: riboflavin + phototherapy**. Neonatal jaundice phototherapy using blue-light wavelengths destroys plasma riboflavin, producing a transient riboflavin deficiency that has been associated with photolysis-induced hemolysis in some case series. Parenteral nutrition bags containing riboflavin must be shielded from light during infusion to prevent riboflavin degradation and reactive oxygen species generation. **Topical riboflavin for corneal crosslinking** is generally well-tolerated. Expected post-procedure effects include 24-48 hours of moderate eye pain, photophobia, tearing, and blurred vision during corneal re-epithelialization. Rare serious adverse effects include sterile corneal infiltrates, corneal haze, infectious keratitis, corneal melting, and endothelial decompensation — these are predominantly associated with infection risk during the de-epithelialized period. Post-procedure use of a bandage contact lens, topical antibiotic, and topical anesthetic/NSAID as directed by the ophthalmologist minimizes these risks. **Pregnancy and lactation**. RDA-range riboflavin (1.4 mg/day in pregnancy, 1.6 mg/day in lactation) is safe and required. Pharmacologic doses for migraine prophylaxis (400 mg/day) have not been specifically studied in large pregnancy cohorts, but the excellent general safety profile, lack of reported teratogenicity, and limited alternatives for migraine preventive therapy in pregnancy make it a reasonable choice under obstetric/neurology supervision. Breastfeeding: RDA-range riboflavin supports maternal and infant needs; high-dose maternal riboflavin has not been associated with infant adverse effects. **Pediatric use**. RDA-range riboflavin is essential. Migraine prophylaxis with riboflavin 200-400 mg/day in children and adolescents has modest evidence and is widely used given the excellent safety profile. Brown-Vialetto-Van Laere syndrome and riboflavin-responsive MADD pediatric high-dose protocols (up to 80 mg/kg/day) are managed by metabolic specialists. **Laboratory monitoring** for chronic pharmacologic riboflavin use is minimal because of the excellent safety profile. Erythrocyte glutathione reductase activity coefficient (EGRAC) is the functional assay of riboflavin status; plasma riboflavin is less sensitive. Routine monitoring is unnecessary for standard migraine-dose use. **No withdrawal syndrome** is associated with riboflavin discontinuation. The cleanest safety summary: riboflavin is one of the safest vitamins at any clinically used dose; the yellow-orange urinary fluorescence is cosmetic-only; drug interactions exist but are rarely clinically significant; topical corneal crosslinking is well-tolerated under ophthalmological supervision; no organ toxicity has been established even at gram-per-day doses.
Where can I buy Riboflavin?
Visit our vendor directory to find trusted sources for Riboflavin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
